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Atherosclerosis is the primary cause of coronary heart disease (CHD), ischemic stroke, 
and peripheral arterial disease. Despite effective lipid-lowering therapies and prevention 
programs, atherosclerosis is still the leading cause of mortality in the United States. 
Moreover, the prevalence of CHD in developing countries worldwide is rapidly increasing 
at a rate expected to overtake those of cancer and diabetes. Prominent risk factors 
include the hardening of arteries and high levels of cholesterol, which lead to the initiation 
and progression of atherosclerosis. However, cell death and efferocytosis are critical 
components of both atherosclerotic plaque progression and regression, yet, few cur-
rently available therapies focus on these processes. Thus, understanding the causes 
of cell death within the atherosclerotic plaque, the consequences of cell death, and the 
mechanisms of apoptotic cell clearance may enable the development of new therapies 
to treat cardiovascular disease. Here, we review how endoplasmic reticulum stress 
and cholesterol metabolism lead to cell death and inflammation, how dying cells affect 
plaque progression, and how autophagy and the clearance of dead cells ameliorates the 
inflammatory environment of the plaque. In addition, we review current research aimed 
at alleviating these processes and specifically targeting therapeutics to the site of the 
plaque.
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iNTRODUCTiON
Cardiovascular disease is the leading cause of morbidity and mortality in the United States and 
its prevalence is rapidly increasing in developing countries (1). Atherosclerosis, the process of 
vascular wall thickening and hardening, is the primary cause of coronary heart disease (CHD), 
ischemic stroke, and peripheral aterial disease (2, 3). Patients currently receive therapeutic cocktails 
containing statins, aspirin, adrenaline β-receptor inhibitors, and angiotensin-converting enzyme 
inhibitors. However, these patients are still confronted with a 70–80% risk of developing a major 
acute cardiovascular event (2, 4). Therapies currently available primarily focus on alleviating 
hypertension and low-density lipoprotein (LDL) cholesterol levels while ignoring the rampant 
levels of inflammation and other causes of cell death in arterial walls and their consequences on 
atherosclerotic progression. This inflammation and cell death drives the transition of the stable 
plaque to a vulnerable plaque, which is prone to rupture leading to thrombosis (5, 6). The instability 
of the plaque is ultimately a result of oxidized LDL (oxLDL) and its pro-inflammatory effects 
on endothelial cell activation and macrophage recruitment and function (6). These oxLDLs are 
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sequestered in the subendothelium where maladaptive inflam-
matory responses to these oxLDLs result in the recruitment, 
infiltration, and differentiation of monocytes into phagocytic 
macrophages (7–10). While these macrophages are initially 
beneficial by clearing the subendotheium of these lipoproteins, 
the macrophages eventually become engorged with lipids result-
ing in dysregulated lipid metabolism and a shift in macrophage 
phenotype to that of lipid-laden foam cells (7, 10, 11). These 
foam cells eventually undergo apoptosis and necrosis, and, when 
not cleared efficiently, release their toxic and pro-inflammatory 
contents into the subendothelial space further promoting cell 
death and inflammation and further increasing the vulnerability 
of the plaque (3). Thus, the discovery of new molecules or 
pathways that inhibit or reduce inflammation, cell death, and 
dyslipidemia would significantly advance efforts to develop new 
and more effect therapies to treat this devastating and prevalent 
disease. Thus, our goal is to analyze several causes of macrophage 
cell death in the plaque including inflammation, cholesterol 
metabolism, endoplasmic reticulum (ER) stress, and mechanisms 
of opposing the inflammatory environment of the plaque and 
clearing dead cells, namely efferocytosis and autophagy in addi-
tion to emerging therapies aimed at these processes.
Atherosclerosis most often develops in areas of low shear 
stress with disturbed or oscillating flow, typically areas 
with branch points, bifurcations, or curvatures (12, 13). In 
these areas of disturbed flow, endothelial cells develop a 
pro-inflammatory phenotype; they exhibit increased produc-
tion of reactive oxygen species, increased cell turnover and 
permeability, shorter glycocalyx, and increased apoptotosis. 
Furthermore, they exhibit increased NF-κB signaling, increased 
expression of leukocyte adhesion molecules, increased produc-
tion of fibronectin, and increased secretion of MCP-1 (13). 
These endothelial cells are further activated by an environ-
ment of hyperlipidemia. LDLs in the circulation interact with 
proteoglycans in the extracellular matrix of the endothelial cells 
where they become sequestered and undergo modifications 
such as aggregation and oxidation becoming proatherogenic 
(14). Exposure of endothelial cells to oxLDL induces the 
expression of MCP-1 (CCL2) and VCAM-1 (6).
P- and E-selectin expressed by endothelial cells loosely 
bind circulating monocytes causing them to role along the 
endothelium as they break and reform bonds with the recep-
tors PSGL-1 and ESL-1 (15, 16). Chemokines sequestered in 
the endothelial glycocalyx activate integrins strengthening the 
adhesion of the monocytes and promoting their transmigration 
from the lumen of the vessel to the subendothelium (15). MCP-1 
is one such chemokine that aids in the recruitment of mono-
cytes expressing CCR2, the MCP-1 receptor (16). Once in the 
subendothelium, the monocytes differentiate into phagocytic 
macrophages (Figure  1A), which are classically activated to 
pro-inflammatory M1 macrophages or alternatively activated 
to anti-inflammatory M2 macrophages. These macrophages 
ingest the lipids sequestered in the subendothelium becoming 
engorged and eventually leading to dysregulated lipid metabo-
lism and foam cell formation (7, 10, 11). These foam cells secrete 
pro-inflammatory cytokines including MCP-1, which recruit 
additional monocytes and macrophages in a positive feedback 
mechanism (15, 16). These foam cells accumulate within the 
subendothelium giving rise to the plaque (Figure  1B). As 
these foam cells undergo apoptosis or necroptosis, a necrotic 
core forms within the plaque (Figure 1C). Plaques with a thin 
fibrous cap and large necrotic cores are likely to rupture leading 
to thrombosis, heart attack, or stroke (5, 17). Furthermore, 
macrophages play a primary role in the clearance of dead 
and dying cells within the plaque enabling plaque regression 
(Figure  1D). Thus, macrophages play a critical role in the 
progression of atherosclerotic plaques. Particularly, the balance 
between macrophage death and the clearance of dead cells by 
macrophages is a determining factor in plaque progression and 
vulnerability.
Additionally, vascular smooth muscle cells (VSMCs) play 
an ever expanding role in the pathogenesis of atherosclerosis. 
VSMCs traditionally produce collagen forming the fibrous cap 
of the lesion and preventing plaque rupture and thrombosis (18) 
(Figure 1D). However, pro-inflammatory cytokines released by 
activated endothelial cells and macrophages promote the altera-
tion of the VSMC phenotype to that of a migratory macrophage-
like phenotype. These macrophage-like VSMCs engulf lipids 
becoming foam cells and contributing to plaque progression (16) 
(Figure 1).
MACROPHAGe DeATH iN THe 
ATHeROSCLeROTiC PLAQUe
In the atherosclerotic lesion, activated macrophages contribute to 
the progression of the lesion by secreting inflammatory cytokines 
(19). In advanced lesions, dead and dying macrophages are not 
efficiently cleared leading to secondary necrosis in which the cells 
become leaky and swollen eventually releasing their contents into 
the subendothelium. This process eventually results in the forma-
tion of the necrotic or lipid core, which is itself an inflammatory 
stimuli to other macrophages in the subendothelium further 
eliciting inflammatory responses and causing cellular damage 
(20). Along with the necrotic core, these activated macrophages 
also promote the thinning of the fibrous cap by releasing pro-
inflammatory cytokines, ROS, and matrix metalloproteinases 
(21). This may eventually lead to the rupture of the fibrous cap 
exposing tissue factor to its ligand and resulting in acute cardio-
vascular events (17, 22, 23).
Several mechanisms are responsible for cell death within the 
plaque. These include both intrinsic and extrinsic apoptosis and 
necroptosis. Apoptosis is driven by the activation of caspases, 
which lead to cell rounding, chromatin condensation, nuclear 
membrane fragmentation, a reduction in cellular volume, and 
membrane blebbing (24). The extrinsic pathway is triggered by 
extracellular signals including damage associated molecular pat-
terns and cytokines. These triggers are sensed by death receptors, 
toll-like receptors, and NOD-like receptors, which propagate 
apoptosis signaling via caspase 8 (24, 25). The intrinsic pathway is 
triggered by intracellular signals such as ER stress, oxidative dam-
age, and DNA damage among others. This pathway propagates 
apoptotic signaling via caspase 3 and caspase 7 (24). Necroptosis 
is regulated necrosis, which leads to cellular swelling and plasma 
membrane rupture. This pathway is activated in response to 
FiGURe 1 | Atherosclerotic plaque progression. (A) Endothelial cells activated by disturbed flow and oxidized low-density lipoprotein (oxLDL) uptake express 
adhesion molecules and chemoattractant proteins that recruit monocytes and promote their adhesion to the endothelium and transmigration into the 
subendothelium. These monocytes differentiate into macrophages. (B) Macrophages uptake oxLDL sequestered in the subendothelium eventually becoming 
lipid-laden foam cells. Vascular smooth muscle cells (VSMCs) can migrate to the subendothelium where they lose expression of SMC markers and gain expression 
of macrophage markers. This allows them to ingest lipids and eventually become foam cells contributing to plaque progression. (C) These foam cells eventually 
undergo apoptosis and necroptosis, and, if not effectively cleared by M2 macrophages via efferocytosis, undergo secondary necrosis contributing to the formation 
of the necrotic core. As the necrotic core grows and the fibrous cap thins, the plaque is vulnerable to rupture, which may result in acute cardiovascular events such 
as thrombosis. (D) VSMCs near the cap of the plaque secrete extracellular matrix components that contribute to the formation of a fibrous cap that protects the 
plaque from rupturing. M2 macrophages express anti-inflammatory markers that act to reduce the inflammation of the plaque. They also perform efferocytosis, 
thereby reducing the apoptotic and necrotic cells within the plaque and promoting plaque stability.
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death receptors, genotoxic stress, and viruses and signals through 
RIPK1, RIPK3, and MLKL (24, 26).
Cell death occurs in lesions throughout the progression of 
atherosclerosis. Gautier et  al. demonstrated that apoptotosis 
in early lesions is atheroprotective but promotes inflammation 
and further plaque progression in advanced lesions. This study 
used ApoE-deficient mice overexpressing Bcl2, a protein which 
inhibits the intrinsic apoptotic pathway. At 5 weeks on Western 
diet, these mice exhibited large lesions with increased numbers of 
macrophages compared to control mice. However, at 15 weeks on 
Western diet, the plaques were smaller with decreased numbers 
of macrophages (27). The extrinsic apoptotic pathway also plays a 
significant role in atherosclerosis. The Fas ligand has been shown 
to be enriched in regions of the plaque that are TUNEL positive 
or apoptotic (28). Furthermore, this pathway has recently been 
linked to ER stress-induced apoptosis specifically in macrophages. 
ER stress induces the release of calcium from the ER. These high 
cytosolic levels of calcium cause the activation of CAMKII, which 
can then induce apoptosis via Fas signaling (29). In addition, 
treating mice with a necroptosis inhibitor greatly reduces plaque 
size and instability (30).
In early lesions, the dying cells are most likely and effectively 
cleared by neighboring macrophages performing efferocytosis, 
the phagocytosis of dying cells, resulting in smaller lesions with 
fewer macrophages. However, in advanced lesions, the vast 
majority of dying cells in need of clearance are macrophages 
(31–34). Since macrophages are the primary cell type responsible 
for efferocytosis within the plaque, it is likely that the large lesion 
size and necrotic core result from inefficient clearance of the dying 
cells and macrophage death itself, likely caused by cholesterol 
loading and ER stress.
eFFeROCYTOSiS iN MACROPHAGeS
Efferocytosis is the clearance of dead and dying cells by phago-
cytes. Efferocytosis functions to clear cells in early stages of cell 
death while the plasma membrane is still intact. It also prevents 
secondary necrosis, thereby preventing the extracellular release 
of the cytotoxic and inflammatory contents of the dying cell 
(35). Dying cells release “find me” signals such as fractalkine or 
CXC3CL1, which establish a chemotactic gradient that stimulates 
the phagocyte to migrate toward the dying cell (36, 37). The dying 
FiGURe 2 | efferocytosis. Efferocytosis is the phagocytosis of dying cells 
by macrophages and is an essential process for the maintenance or 
regression of the atherosclerotic plaque. Phosphatidylserine (PS) among 
other molecules are “eat me” signals expressed on the dying cell, which are 
recognized by receptors on the phagocyte. Binding of PS by these receptors 
results in Rac1 activation and actin reorganization as well as PPAR and LXR 
signaling. PPAR and LXR signaling result in the upregulation of proteins 
involved in binding the dying cell as well as proteins involved in cholesterol 
efflux and anti-inflammatory cytokines ultimately promoting an anti-
inflammatory M2 macrophage phenotype. The dying cell is engulfed and 
digested, its inflammatory contents cleared from the subendothelium. In 
advanced plaques, apoptosis and efferocytosis become dysregulated and 
imbalanced. Apoptotic cells that express “don’t eat me” signals evade uptake 
by phagocytes and eventually undergo secondary necrosis contributing to 
the development of the necrotic core.
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cells also display “eat me” signals on their surface, which are 
recognized by specific receptors on the phagocyte. These ligand 
receptor pairs include calreticulin or complement C1q with LRP-
1, thrombosopondin and CD36, and phosphatidylserine (PS) 
with SR-BI, integrins, and TIM-4 among others (37). Once the 
phagocytic receptor binds its ligand on the dying cell, a series of 
signaling events occur in the phagocyte that result in the activa-
tion of Rac-1, actin rearrangement, phagocytic cup formation, 
and engulfment of the dying cell (Figure 2). Once the dying cell 
is internalized, it and its contents are degraded (38). There are 
two main methods of engulfment: the phagocytic membrane is 
extended around the dying cell and closes like a zipper forming 
a tight fitting phagosome (39, 40), while necrotic cells are inter-
nalized in a fluid-filled phagosome much like macropinocytosis 
(40, 41). However, both methods converge on the same signaling 
pathways for phagocyte recognition and actin rearrangement 
(42). Thus, efferocytosis, in the context of the atherosclerotic 
plaque, acts to reduce the apoptotic and necrotic burden within 
the plaque, thereby reducing the probability of the formation of 
a vulnerable, rupture prone plaque. Furthermore, efferocytosis 
actively promotes an anti-inflammatory environment within the 
plaque. Treatment of primary macrophages with fractalkine prior 
to co-incubation with apoptotic thymocytes induced expression 
of MFG-E8, a bridging molecule involved in the binding of the 
phagocyte to the apoptotic cell, and increased phagocytosis (43). 
Through the ingestion of dying foam cells, efferocytosis provides 
phagocytic macrophages with large amounts of lipids, which are 
PPAR and LXR ligands (44). PPAR and LXR signaling induce the 
expression of genes involved in sensing “eat me” signals such as 
C1q, a bridging molecule, and Mertk, an efferocytic receptor (45). 
This increase in Mertk further stimulates an increase in its cor-
responding bridging molecule, Gas6 (45, 46). LXR signaling via 
apoptotic cell recognition also induced the expression of ABCA1 
and ABCG1 resulting in a significant increase in cholesterol 
efflux from macrophages (16, 19, 47, 48). PPAR and LXR signal-
ing also result in the increased production and release of anti-
inflammatory signals such as IL-10, induces anti-inflammatory 
M2 macrophage polarization, and suppresses pro-inflammatory 
signals such as TNFα and IL-1β as well as inhibiting NFκB gene 
transcription, which is a key mechanism of M1 activation (49–53). 
Thus, efferocytic signaling further enhances efferocytosis and acts 
to resolve the inflammation present within the plaque (Figure 2).
Recent studies have made it apparent that, in the advanced 
plaque, efferocytosis is dysregulated, either through the overabun-
dance of dying cells or the inability of macrophages to efficiently 
perform phagocytosis. Severe deficiency in efferocytosis has been 
demonstrated in human atherosclerotic plaques (54). Despite the 
numerous receptors and ligands involved in apoptotic cell clear-
ance and their apparent overlap in function, simply disrupting 
one receptor can cause a significant deficiency in efferocytosis. 
Several studies have demonstrated that reduction of LRP-1, spe-
cifically in macrophages, or its ligand, calreticulin, significantly 
reduces efferocytosis while simultaneously enhancing the inflam-
matory phenotype of macrophages, foam cell formation, and 
plaque progression in mice (55–57). Another study used LDLR 
null mice, which were treated with anti-TIM-1 and anti-TIM4 
antibodies to block TIM-1 and TIM-4 binding to PS and thereby 
inhibiting efferocytosis. These mice exhibited increased ath-
erosclerotic lesion size as well as increased macrophage content 
within lesions. TIM-4 blockade specifically impaired efferocyto-
sis as demonstrated in cultured primary peritoneal macrophages, 
while TIM-1 blockade promoted proatherogenic Th1 cells (58). 
Furthermore, transplanting SR-BI null myeloid cells into ApoE 
null mice fed Western diet significantly increased macrophage 
apoptosis within the lesion as well as lesion necrosis. This also 
resulted in reductions of efferocytosis and Rac-1 signaling (59). 
While it is known that oxLDL reduces the expression of SR-BI, the 
exact mechanisms regulating the expression of proteins involved 
in efferocytosis are not entirely clear (60). Thus, illuminating 
mechanisms that downregulate or upregulate proteins involved 
in efferocytosis is critical for the development of new therapies. 
Molecules present in the pro-inflammatory environment have 
been shown to regulate efferocytosis. Mertk, has been shown to 
undergo shedding, or release of its extracellular domain, when 
exposed to metalloproteinases, which are highly expressed in the 
lesion. Mertk shedding resulted in reduced apoptotic cell clearance 
(61). When ADAM17, the primary metalloproteinase responsible 
for Mertk shedding, is genetically deleted from mice, primary 
macrophages exhibit an M2 anti-inflammatory phenotype with 
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increased efferocytosis and increased resolution of inflamma-
tion (62). These studies demonstrate that the pro-inflammatory 
environment within the plaque can impair efferocytosis by 
downregulating the expression or function of proteins involved 
in the clearance of dead and dying cells. Conversely, a recent study 
by Kojima et al. demonstrated that blocking CD47 reduces plaque 
burden and enhances efferocytosis in mice. CD47 functions as 
an antiphagocytic “don’t eat me” signal that is upregulated in 
atherosclerosis (41). When ApoE null mice fed Western diet 
were treated with anti-CD47 antibodies to block CD47 function, 
these mice exhibited decreased lesion size, decreased necrotic 
core area and caspase activity indicative of decreased cell death, 
and increased plaque stability. Furthermore, in vitro efferocytosis 
analysis with primary macrophages and staining of aortic root 
lesions demonstrated increased efferocytosis. The authors went 
on to demonstrate that the expression of CD47 is induced by 
TNFα, a pro-inflammatory cytokine present within the plaque. In 
addition, treatment of primary VSMCs with TNFα reduced their 
susceptibility to apoptosis as well as reducing their efferocytic 
uptake by primary macrophages (63). Developing molecules to 
downregulate other such “don’t eat me” signals presents another 
potential therapeutic strategy.
CHOLeSTeROL MeTABOLiSM iN 
MACROPHAGeS
Reverse cholesterol transport is the transport of cholesterol 
back to the liver from the circulation for excretion in the bile 
and feces. Macrophages play an essential role in the process 
both through cholesterol uptake and cholesterol efflux. The 
receptors primarily responsible for the uptake of oxLDL are 
CD36, SR-AI, SR-AII, and LOX-1. OxLDLs are also taken up 
by micropinocytosis, which is mediated by TLR4. After the 
lipoproteins are transported into the macrophage, the cholesteryl 
esters are hydrolyzed to free cholesterol in late endosomes. The 
free cholesterol is then esterified by ACAT1 and stored in the 
ER as lipid droplets. The cholesterol esters undergo secondary 
hydrolysis prior to being transferred out of the cell via passive 
diffusion or scavenger receptors ABCA1, ABCG1, and SR-BI 
during cholesterol efflux (64, 65).
In atherosclerosis, the process becomes dysregulated. In 
conditions of hyperlipidemia, activated macrophages uptake 
large amounts of oxLDL. However, this does not downregulate 
the expression of CD36, the SR-As, or LOX-1. In fact, several 
pro-inflammatory cytokines prominent in the plaque including 
IFN-γ, TNF-α, and IL-1β, promote the upregulation of the SR-As, 
CD36, and LOX-1 while downregulating ABCA1 and ABCG1 
(66), thereby enhancing cholesterol uptake while simultaneously 
inhibiting cholesterol efflux and contributing to enhanced foam 
cell formation. When these foam cells accumulate an excess of 
free cholesterol, they can undergo apoptosis or necrosis contrib-
uting to plaque progression, necrotic core formation, and plaque 
rupture (67–69). Furthermore, macrophages engulf cholesterol 
crystals, which form in the arterial wall. These crystals can 
trigger inflammasome activation via NLRP3 leading to IL-1β 
secretion (70). This further perpetuates the cycle of inflamma-
tion and macrophage death within the plaque ultimately leading 
to plaque progression. In addition, when macrophages undergo 
apoptosis due to free cholesterol accumulation, they induce 
the production of the pro-inflammatory cytokines TNF-α and 
IL-1β in competent phagocytic macrophages. This results in a 
pro-inflammatory M1 phenotype (71). Thus, the dysregulation 
of cholesterol metabolism in macrophages acts to promote the 
pro-inflammatory environment within the plaque as well as mac-
rophage death resulting in plaque progression and the formation 
of the necrotic core.
eR STReSS iN eNDOTHeLiAL CeLLS 
AND MACROPHAGeS
Under normal conditions, IRE1, PERK, and ATF6, three trans-
membrane proteins, extend through the ER membrane into 
the ER lumen. In the lumen, they are inactive when bound to 
chaperones involved in protein folding (16). Ischemia, hypoxia, 
excess protein synthesis, ROS, and excess free cholesterol, and 
disordered lipid composition within a cell can lead to ER stress 
(72, 73). In response to ER stress, protein chaperones are upregu-
lated and PERK and IRE1 become oligomerized and activated 
initiating the unfolded protein response (UPR) (74, 75). The UPR 
acts to reduce protein synthesis, enhance protein degradation, 
and increase protein folding ultimately resulting in the reduction 
of stress in the ER. Specifically, PERK acts to suppress general 
protein translation, IRE1 activates inflammatory and survival 
signaling pathways, and ATF6 is processed by proteases in the 
Golgi apparatus forming a transcription factor, which upregulates 
ER chaperones (74–76). However, continued ER stress and UPR 
activation can lead to cell death.
Under normal conditions, endothelial cells create barrier 
separating molecules circulating in the blood stream from 
the subendothelium. However, as the endothelial cells become 
activated, this endothelial barrier begins to break down becom-
ing leaky. In addition to the transendocytosis of lipoproteins 
into the subendothelium, this further enables circulating 
lipoproteins to be taken up into the subendothelium and 
modified (77). This endothelial cell dysfunction also results in 
the production of chemokines that recruit monocytes to the 
subendothelium and contribute to an environment that enables 
the phenotypic switching of VSMCs resulting in their increased 
proliferation and increased production of extracellular matrix 
components, which contribute to the fibrous cap of the plaque 
(78). ER stress has been shown to be a prominent cause of 
endothelial cell dysfunction. Disturbed flow, known to activate 
the endothelium, may also promote ER stress in endothelial 
cells. Phospho-ATF6 and phospho-IRE1 have been shown to 
be upregulated in endothelial cells in regions of disturbed flow 
(79); the phosphorylation of these two proteins is indicative of 
ER stress and activation of the UPR. Furthermore, endothelial 
cells exposed to disturbed flow have a larger burden of ROS 
compared to endothelial cells not exposed to disturbed flow; 
ROS is known to induce ER stress in endothelial cells (79), 
OxLDL and disturbed flow in endothelial cells has been shown 
to upregulate the expression of LOX-1, the primary receptor in 
endothelial cells responsible for the uptake of oxLDL (80, 81). 
OxLDL has also been demonstrated to activate endothelial cell 
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CHOP and caspase 12, both involved in the activation of the UPR 
(82). Thus, disturbed flow and oxLDL activate the endothelium 
possibly by inducing ER stress in endothelial cells eventually 
leading to endothelial cell dysfunction.
Several studies have demonstrated the contribution of ER 
stress and the UPR to macrophage death and necrotic core 
formation within atherosclerotic plaques. At all stages of lesion 
development, the UPR is activated. Markers for UPR activation, 
including phospho-PERK and CHOP, along with free cholesterol 
accumulation have been observed in both early and advanced 
atherosclerotic lesion of mice (83). Furthermore, exposure of 
THP-1 macrophages to oxLDL induced intracellular accumula-
tion of 7-ketocholesterol, which upregulates ER chaperones and 
CHOP expression leading to UPR activation. Furthermore, this 
treatment caused the macrophages to undergo oxidative stress and 
increase the expression and secretion of MMP9 (84). Oxidative 
stress promotes cellular damage contributing to the inflammatory 
environment of the plaque and cell death while MMP9 degrades 
the extracellular matrix weakening the fibrous cap and creating 
a rupture prone plaque. In addition, cholesterol trafficking to ER 
membranes has been shown to induce the UPR and the activation 
of CHOP, which is induced by ER stress and mediates apoptosis. 
This occurs through the depletion of ER calcium stores, which 
has also been demonstrated to activate the UPR. Furthermore, 
CHOP null macrophages were protected from cholesterol-
induced death (72). Thus, in hyperlipidemia, oxLDL uptake 
and cholesterol loading of macrophages in the plaque initially 
clears the subendothelium of these pro-inflammatory stimuli but 
eventually results in the dysregulation of cholesterol metabolism, 
ER stress, cell death, necrotic core formation, and plaque rupture. 
The clearance of these macrophages is of the upmost importance 
in preventing the progression of the plaque and eventual acute 
cardiovascular events.
AUTOPHAGY iN eNDOTHeLiAL CeLLS, 
vSMCs, AND MACROPHAGeS
Under non-pathological conditions, autophagy functions 
to degrade large cellular structures and aggregated proteins. 
Autophagy consists of two steps beginning with the formation of 
the autophagosome, a double membrane vesicle that engulfs cyto-
plasm containing misfolded proteins or damaged organelles (85, 
86). These autophagosomes shed their coat proteins and then fuse 
with lysosomes forming a single membrane autolysosome. The 
contents are degraded and recycled for anabolic reactions within 
the cell (85–87). When functioning appropriately, autophagy 
reduces apoptosis within the plaque, thereby increasing plaque 
stability (85, 86). However, several studies have shown that dys-
regulation of autophagy in multiple cell types is associated with 
atherosclerosis.
Properly functioning autophagy is essential for lipid homeo-
stasis in endothelial cells. Knockdown of Atg7, a protein involved 
in autophagosome elongation, in HUVECs resulted in the 
accumulation of intracellular oxLDL. Endothelial cell-specific 
knockout of Atg7 in ApoE null mice also demonstrated intra-
cellular accumulation of oxLDL with increased atherosclerotic 
lesion size containing larger necrotic areas (88). Several studies 
have demonstrated that disturbed flow and oxLDL not only pro-
mote endothelial cell activation but dysregulation of autophagy. 
Significant downregulation of Beclin1, LC3II, and LC3I were 
observed in endothelial cells exposed to disturbed flow compared 
to those exposed to physiological shear stress (89). Given that 
Beclin-1 is required for autophagosome formation and the LC3 
proteins coat the autophagosome aiding in lysosome fusion, 
endothelial cell exposure to oxLDL results in the dysregula-
tion of autophagy, thereby enhancing the pro-inflammatory 
environment of the plaque (85). HUVECs treated with oxLDL 
exhibit damaged mitochondrial DNA (mtDNA). Under pro-
atherosclerotic conditions when autophagy is defective, this 
mtDNA leaks into the cytoplasm and initiates an inflammatory 
response dependent on TLR9 (90). Furthermore, VSMCs exposed 
to low levels of oxLDL exhibited increased expression of LOX-1 
and increased autophagy. However, when the concentration of 
oxLDL was increased to reflect the loss of cellular defenses in 
atherosclerotic plaques, autophagy and apoptosis were induced 
(91). 7-Ketocholesterol is found in atherosclerotic plaques and 
is known to induce ER stress. When VSMCs are treated with 
7-ketocholesterol, they accumulate ubiquitinated proteins, 
thereby activating the UPR and eventually leading to defective 
autophagy and cell death (92). Thus, autophagy is an essential 
process for maintaining lipid homeostasis but one that is suscep-
tible to dysregulation in an atherosclerotic environment.
Atg5 is another protein involved in the elongation of the 
autophagosome (87). When this protein is selectively knocked out 
in macrophages in ApoE null mice, macrophages exhibit increased 
apoptosis and oxidative stress but decreased phagocytic clearance 
in  vitro and promote plaque necrosis, macrophage apoptosis, 
and oxidative stress within the plaque (93). Another study using 
this mouse model demonstrated that advanced plaques exhibit 
markers consistent with dysfunctional autophagy. In addition, 
macrophage-specific deficiency of Atg5 increased the cholesterol 
crystal burden within the plaque as well as the activation of the 
macrophage inflammasome further promoting the progression 
of atherosclerosis in these mice (94). Furthermore, decreased 
autophagy has been demonstrated in foam cells. Treatment of 
macrophages with the autophagy activator rapamycin exhibited 
reduced lipid content resulting in reduced foam cell formation 
in vitro (95). Thus, the dysregulation of autophagy may be a con-
tributing factor to the formation of lipid-laden foam cells in the 
progression of atherosclerosis. Agents that enhance the function 
of authophagy may prove vital for the improvement of treatments 
for patients with CHD.
Lipophagy is a form of selective autophagy in which lipid 
droplets are delivered to the lysosome for degradation and has 
been demonstrated in hepatocytes (96). It is now understood 
that this process also occurs in macrophages and has an impact 
on cholesterol metabolism. It has been previously shown that 
foam cells deliver a portion of their neutral lipids to lysosomes 
for hydrolysis in addition to the cytoplasm (97). Furthermore, 
lipid droplets sequestered in autophagosomes have been dem-
onstrated to be delivered to lysosomes. Here, the lipid droplets 
undergo hydrolysis via lysosomal acid lipase to form free cho-
lesterol, which is then effluxed out of the cell (98). Agents that 
can induce this pathway of cholesterol metabolism may enhance 
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cholesterol efflux, thereby reducing foam cell formation and 
plaque progression.
vSMC PHeNOTYPe SwiTCHiNG AND 
CONTRiBUTiON TO PLAQUe 
PROGReSSiON
Historically, the role of VSMCs in atherosclerosis has been 
simple: their proliferation promotes plaque formation and their 
production of collagen, which expands the extracellular matrix 
of the endothelium and forms the fibrous cap (99). However, 
recent studies suggest a far more complex role for these cells in 
the progression of atherosclerosis. Several studies have shown 
that cultured VSMCs could gain a macrophage-like phenotype 
while losing expression of characteristic VSMC markers as 
evidenced by co-staining of smooth muscle actin (SMA) and 
CD68 (macrophage marker) in human atherosclerotic lesions 
(100–103). However, these studies were unable to determine if 
these cells were of smooth muscle origin or not. A genetic induc-
ible fate-mapping study using ApoE null mice in which smooth 
muscle cells and their progeny exhibited β-galactosidase activity 
used both Western blot and tissue staining to demonstrate the 
upregulation of macrophage markers MAC-2 and CD68 and 
downregulation of smooth muscle cell markers SMA and smooth 
muscle myosin heavy chain with concomitant β-galactosidase 
activity in cultured VSMCs derived from atherosclerotic aortas 
compared to non-atherosclerotic aortas (104). A second smooth 
muscle cell lineage tracing study showed that over 80% of 
VSMCs, approximately 30% of total cells, within atherosclerotic 
lesions are undetectable using conventional SMA staining. 
These cells undergo a phenotypic transition within the lesion 
to a more macrophage-like phenotype. Furthermore, the loss 
of KLF4 within SMCs resulted in a reduction of VSMCs with 
a macrophage-like phenotype within the lesion in addition to 
reduced lesion size and reduced fibrous cap thickness. This 
study also elucidated a role for VSMCs in foam cell formation. 
Upon cholesterol loading, KLF4 expression and expression 
of macrophage markers were induced in VSMCs resulting in 
phagocytic behavior and the expression of pro-inflammatory 
cytokines (105). Much like macrophages, these phenotypically 
altered VSMCs exhibit expression of SR-As, CD36, and LOX-1 
and downregulation of ABCA1 and ABCG1 indicating increased 
oxLDL uptake and reduced cholesterol efflux resulting in foam 
cell formation (106–108). Furthermore, oxLDL has been shown 
to activate the TLR4-mediated inflammatory signaling pathway 
in VSMCs. This results in the upregulation of ACAT1 expres-
sion further promoting intracellular lipid accumulation and 
foam cell formation (109). These lipid-laden VSMCs can also 
undergo cholesterol-induced cell death resulting in the release 
of MCP-1, fractalkine, and other pro-inflammatory cytokines 
that recruit monocytes, promoting further VSMC phenotype 
switching, and enhancing plaque development (110). Given the 
similarities between these phenotypically altered VSMCs and 
macrophages, it is probable that the same mechanisms lead to 
cell death, namely ER stress, and dysregulation of cholesterol 
metabolism and autophagy. Furthermore, VSMCs likely play a 
significant role in plaque progression by contributing to the foam 
cell formation, cell death, and necrotic core formation within 
the plaque.
THeRAPeUTiC iMPLiCATiONS AND 
FUTURe DiReCTiONS
Many current therapies used to treat patients with cardiovas-
cular disease focus on ameliorating hypertension and lowering 
lipid levels. However, these treatments yield less than ideal 
results. New treatments that address the high levels of inflam-
mation and cell death and low levels of dead cell clearance 
may help to fill this gap. Much research has been done to 
examine the effectiveness of reducing ROS and inflammation 
in atherosclerosis as therapeutic options for CVD. While it is 
enticing to develop therapies to reduce cell death within the 
atherosclerotic lesion, this may ultimately prove detrimental. 
As previously stated, apoptosis in early lesions reduces plaque 
size while apoptosis in more advanced lesions promotes the 
formation of the necrotic core and increases plaque vulner-
ability. Furthermore, the digestion of these apoptotic cells by 
phagocytic macrophages promotes anti-inflammatory signaling 
and cholesterol efflux, two processes which promote plaque 
regression. Considering that eliminating one efferocytic recep-
tor on macrophages significantly impairs efferocytosis as a 
whole, developing therapies that enhance efferocytosis, either 
by promoting “eat me” signals or their receptors, may be a 
more effective therapeutic strategy.
ROS contribute both to inflammatory signaling in the 
atherosclerotic plaque and ER stress in endothelial cells, mac-
rophages, and VSMCs. Thus, antioxidant therapies designed to 
counter ROS may prove effective in reducing plaque progression, 
inflammation, and cell death. Several studies have focused on 
compounds found in food that have been shown to have antioxi-
dant properties such as vitamins C and E. Vitamin C scavenges 
ROS, reduces pro-inflammatory cytokine levels, and prevents 
endothelial cell apoptosis (111). Several forms of vitamin E have 
been shown to reduce ROS production by inhibiting NADPH 
oxidase and scavenge-free radicals (112). Various studies in 
humans with vitamins C and E have shown conflicting results 
showing beneficial, neutral, and harmful effects of these com-
pounds, which are extensively reviewed elsewhere (113–115). 
However, the contrasting results among these studies could be 
due to differences in doses, time course, patient populations, the 
use of food-derived versus synthetic vitamins, and the use of dif-
ferent forms of Vitamin E, not all of which have the same effects 
(114, 116). Thus, further studies with more standardized methods 
or utilizing more targeted delivery methods may be needed to 
truly evaluate the potential of vitamins C and E as therapies for 
atherosclerosis.
Several other therapies have been developed recently to com-
bat the role of ROS in the development and progression of ath-
erosclerosis. Xanthine oxidoreductase (XOR) is highly expressed 
in atherosclerotic plaques and is known to produce ROS and 
promote the progression of atherosclerosis (117–119). When ath-
erosclerotic mice are treated with the XOR inhibitor febuxostat, 
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they exhibit reduced atherosclerotic lesion size and macrophage 
infiltration into the plaque, and reduced ROS levels in the aortic 
wall, as well as reduced expression of pro-inflammatory genes 
within the aorta (120). Thus, inhibiting the enzymes responsible 
for ROS production may prove to be a valuable therapeutic option 
for CVD. Tian et  al. synthesized quercetin 7-0-sialic acid to 
combine the ROS scavenger sialic acid and quercetin, which 
has been shown to be an anti-inflammatory antioxidant that 
promotes cholesterol efflux. This compound protected HUVECs 
from hydrogen peroxide and oxLDL-induced oxidative damage 
by reducing the production of ROS. It also reduced the expres-
sion of the adhesion molecules ICAM1 and VCAM1 as well 
as the pro-inflammatory cytokines TNFα and MCP-1 in these 
cells, suggesting that aortic endothelial cells treated with this 
agent would recruit fewer monocytes. Furthermore, RAW264.7 
cells, a mouse macrophage-like cell line, exhibited upregulation 
of ABCA1 and ABCG1 resulting in increased cholesterol efflux 
when treated with 7-0-sialic acid (121). While both quercetin 
and sialic acid have anti-atherosclerotic properties on their 
own, combining these into one compound greatly increased 
their effects (121). Thus, combining other molecules with 
individual antiatherosclerotic properties may prove an effective 
method for creating new, more effective treatments for CVD. 
Szeto and Schiller developed SS-31, a peptide that acts as an 
antioxidant by scavenging reactive oxygen species specifically 
in the inner mitochondrial membrane (122). This peptide is 
currently in phase II clinical development; however, its potential 
use in treating cardiovascular disease has only recently been 
demonstrated (123). SS-31 has been shown to both reduce oxLDL 
accumulation, at least partially by downregulating CD36 and 
LOX-1, and suppress oxLDL-induced ER stress in RAW264.7 
cells. Furthermore, treatment of RAW264.7 cells with this peptide 
reduced oxLDL-induced inflammation by reducing IL-6 and 
TNFα secretion (124). While both of these compounds are 
promising, further study, particularly whole animal studies, need 
to be completed to provide a clearer picture of their effectiveness 
in treating CVD.
Enhancement or inhibition of several molecules found in 
mammals have also shown promises as potential therapies for 
CVD. Growth differentiation factor 11 (GDF11) is associated 
with lower risk of CVD, but its levels decline in circulation 
with age (125). When this growth factor was administered to 
ApoE null mice on high fat diet, endothelial cells from these 
mice exhibited reduced endothelial dysfunction and reduced 
apoptosis of primary endothelial cells. GDF11 also reduced 
atherosclerotic lesion size in mice as well as pro-inflammatory 
cytokine expression in RAW264.7 cells (126). Thus, GDF11 
represents a promising potential therapy to ameliorate multiple 
aspects of atherosclerotic plaque progression. Pro-resolving 
mediators, such as Resolvin D1, have been shown to inhibit pro-
inflammatory signaling and enhance anti-inflammatory signal-
ing (127). Resolvin D1 has been shown to be significantly reduced 
in both human vulnerable plaques and advanced murine plaques 
most likely due a mechanism involving oxidative stress. When 
atherosclerotic mice are treated with Resolvin D1, oxidative stress 
and necrotic core size within the plaque are reduced while cap 
thickness and efferocytosis are increased (128). Promoting the 
resolution of inflammation is a promising therapeutic area to 
affect multiple aspects of plaque progression. TREM-1 is a recep-
tor expressed on monocytes and macrophages, which has been 
shown to enhance the production of pro-inflammatory cytokines 
and chemokines such as CCL2 and TNFα, which are involved in 
the promotion of plaque progression, while hindering the release 
of anti-inflammatory cytokines such as IL-10 (129). A recent 
study found that atherosclerotic mice with a TREM-1 deficiency 
exhibited reduced macrophage recruitment, necrotic core size 
within plaques, reduced foam cell formation, reduced pro-
inflammatory cytokine secretion, and ultimately reduced plaque 
size compared to control mice. Furthermore, these results were 
replicated by treating atherosclerotic mice with the LR12 peptide, 
which inhibits TREM-1 binding to its endogenous ligand, these 
mice (130). Thus, blocking the agents of inflammation, namely 
monocytes, from entering the atherosclerotic plaques represents 
a viable and potent therapy for atherosclerosis.
A significant challenge in CVD therapy development is 
treating cells in areas affected in the disease or specific cell 
types as opposed to multiple cell types throughout the body. 
Furthermore, targeting treatments, such as antioxidants and 
resolving mediators, to specific cell types, organelles, or specific 
regions of the body may enhance their effectiveness in ameliorat-
ing atherosclerosis. Recent work has focused on this issue of tar-
geting therapies and has shown promising results with molecules 
targeted to the mitochondria aimed at resolving oxidative stress 
originating from this organelle. MitoQ, a derivative of the anti-
oxidant ubiquinone conjugated to a lipophilic cation, enters and 
accumulates within the mitochondria (131–133). This molecule 
has been shown to reduce endothelial dysfunction and reduce 
not only cellular and mitochondrial ROS but also the secre-
tion of pro-inflammatory cytokines (134, 135). Furthermore, 
when atherosclerotic mice that were also haploinsufficient for 
ATM were treated with MitoQ, they exhibited decreased fat 
accumulation and oxidative stress, and improved lipid and 
glucose metabolism compared to control treated mice. Despite 
a lack of change in atherosclerotic plaque size, macrophage 
content, apoptosis, and oxidative damage were significantly 
reduced within the plaques at least indicating a more stable 
plaque compared to control treated mice (136). Mitochondrial-
targeted Vitamin E has been shown to reduce oxidative stress and 
apoptosis is primary endothelial cells (137). Furthermore, several 
studies in mouse models of sepsis have shown this molecule to 
reduce oxidative stress and inflammatory cytokine production 
(138, 139). Esculetin is another antioxidant whose functions 
have gained increased efficacy through mitochondrial targeting. 
Karnewar et  al. demonstrated that this compound alleviated 
oxidative stress and cell death by increasing the phosphorylation 
of eNOS resulting in increased NO production in human aortic 
endothelial cells. Furthermore, atherosclerotic mice treated 
with this molecule exhibited reduced plaque size and reduced 
monocyte and macrophage infiltration into the plaque (140). 
While studies involving mitochondrial-targeted antioxidants are 
promising, more studied are needed both in atherosclerotic and 
human models. Resolving mediators, such as annexin A1, func-
tion to terminate inflammation and promote tissue repair (141). 
Fredman et  al. recently designed an amino terminal peptide 
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that mimics the function of annexin A1. Nanoparticles were 
used to deliver this peptide specifically to sites of injury using 
a collagen IV-binding peptide. When LDLR null mice were 
treated with this compound, the nanoparticles were detected in 
atherosclerotic lesions within aortic root sections with reduced 
detection at other sites such as the spleen and liver. This amino 
terminal peptide resulted in increased fibrous cap thickness 
and suppression of oxidative stress within the plaque as well as 
reduced necrosis. Ultimately, the site-specific delivery of this 
peptide resulted in reduced atherosclerotic lesion size in these 
mice (142). Chung et  al. identified a novel peptide that binds 
specifically to endothelial cells exposed to disturbed flow. To 
evaluate this peptide as a potential therapeutic strategy, it was 
used to deliver siRNA targeting ICAM-1 in a partial carotid liga-
tion mouse model. This resulted in reduced ICAM-1 expression 
in aortas under conditions of disturbed flow potentially resulting 
in reduced monocyte recruitment (143). Thus, nanoparticles and 
targeted peptides greatly enhance the ability to specifically treat 
atherosclerotic prone regions and represent a rapidly growing 
area in cardiovascular research.
CONCLUSiON
Atherosclerosis is, in part, a progressive inflammatory disease 
that is exhibited by increased apoptosis and defective clearance 
of dead cells. Both cholesterol metabolism and ER stress contrib-
ute to these processes. Given the complexity of atherosclerosis 
progression, it is not surprising that current treatments are largely 
ineffective. Current therapies ignore the inflammation and cell 
death within the atherosclerotic lesion. Unfortunately, these 
processes drive plaque progression and vulnerability. Thus, 
elucidating the pathways that control this feedforward cycle of 
inflammation and death may illuminate new molecules that can 
aid in the development of new therapies. Such pathways worthy 
of focus are cholesterol metabolism, cytokine production, and ER 
stress all of which promote a pro-inflammatory environment and 
cell death. Furthermore, enhancing the proper recycling of dam-
aged organelles and lipids via autophagy as well as augmenting 
efferocytosis either through the downregulation of “don’t eat me” 
signals or the upregulation of “eat me signals” and their receptors 
may also prove to be effective therapeutic options.
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